Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Askoxylakis, Vasileios ^a,b   Dinkel, Julien ^b   Eichinger, Monika ^b   Stieltjes, Bram ^b   Sommer, Gregor ^b   Strauss, Ludwig G ^b   Dimitrakopoulou Strauss, Antonia ^b   Kopp Schneider, Annette ^b   Haberkorn, Uwe ^a   Huber, Peter E ^a,b   Bischof, Marc ^a   Debus, Jürgen ^a,b   Thieke, Christian ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Hypoxia; Imaging; Non small cell lung cancer; Radiotherapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HYPOXIA; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REOXYGENATION; TREATMENT OUTCOME; TUMOR HYPOXIA;

ALGORITHMS; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MISONIDAZOLE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84866156414     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-157     Document Type: Article

References (31)

1. Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010, 10:105. 10.1186/1471-2407-10-105, 2851688, 20307299.
2. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 52:382-389. 10.1016/S0360-3016(01)01823-5, 11872283.
3. Anderson CS, Curran WJ. Combined modality therapy for stage III non-small-cell lung cancer. Semin Radiat Oncol 2010, 20:186-191. 10.1016/j.semradonc.2010.01.007, 20685581.
4. Lee CB, Stinchcombe TE, Moore DT, Morris DE, Hayes DN, Halle J, Rosenman JG, Rivera MP, Socinski MA. Late complications of high dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol 2009, 4:74-79. 10.1097/JTO.0b013e3181915028, 19096310.
5. Christian JA, Bedford JL, Webb S, Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 67:735-741. 10.1016/j.ijrobp.2006.09.047, 17187941.
6. De Ruysscher D, Nestle U, Jeraj R, Macmanus M. PET scans in radiotherapy planning of lung cancer. Lung Cancer 2012, 75(2):141-145. 10.1016/j.lungcan.2011.07.018, 21920625.
7. Yaremko BP, Guerrero TM, Noyola-Martinez J, Guerra R, Lege DG, Nguyen LT, Balter PA, Cox JD, Komaki R. Reduction of normal lung iradiation in locally advanced non-small-cell lung patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys 2007, 68:562-571. 10.1016/j.ijrobp.2007.01.044, 3490190, 17398028.
8. Ford EC, Mageras GS, Yorke E, Ling CC. Respiration-correlated spiral CT: a method of measuring respiratory-induced anatomic motion for radiation treatment planning. Med Phys 2003, 30:88-97. 10.1118/1.1531177, 12557983.
9. Guerrero T, Sanders K, Castillo E, Zhang Y, Bidaut L, Pan T, Komaki R. Dynamic ventilation imaging from four-dimensional computed tomography. Phys Med Biol 2006, 51:777-791. 10.1088/0031-9155/51/4/002, 16467578.
10. Fujimoto K. Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules. Cancer imaging 2008, 3:36-44.
11. Henzler T, Schmid-Bindert G, Schoenberg SO, Fink C. Diffusion and perfusion MRI of the lung and mediastinum. Eur J Radiol 2010, 76:329-336. 10.1016/j.ejrad.2010.05.005, 20627435.
12. Demir R, Naschberger L, Demir I, Melling N, Dimmler A, Papadopoulus T, Sturzl M, Klein P, Hohenberger W. Hypoxia generates a more invasive phenotype of tumour cells: An in vivo experimental setup based on the chorioallantoic membrane. Pathol Oncol Res 2009, 15:417-422. 10.1007/s12253-008-9140-y, 19082873.
13. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol 2010, 20:156-163. 10.1016/j.semradonc.2010.01.003, 2917385, 20685578.
14. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003, 67:3-15. 10.1016/S0167-8140(03)00011-2, 12758235.
15. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 2007, 37:451-461. 10.1053/j.semnuclmed.2007.07.001, 17920352.
16. Zimny M, Gagel B, Dimartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U, Reinarzt P. FDG-a marker of tumour hypoxia? A comparison with [(18 F]fluoromisonidazole and pO (2)-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006, 33:1426-1431. 10.1007/s00259-006-0175-6, 16841141.
17. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18 F]FDG and [18 F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006, 80:151-156. 10.1016/j.radonc.2006.07.033, 16920211.
18. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R. Prognostic impact of hypoxia imaging with 18 F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005, 46:253-260.
19. Gagel B, Reinarzt P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ. [18 F]fluoromisonidazole and [18 F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006, 6:51. 10.1186/1471-2407-6-51, 1456976, 16515707.
20. Pacheco-Torres J, López-Larrubia P, Ballesteros P, Cerdán S. Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed 2011, 24:1-16. 10.1002/nbm.1558, 21259366.
21. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, Haberkorn U, Strauss LG. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol 2007, 9:308-317. 10.1007/s11307-007-0103-6, 17623254.
22. Lemke A, Laun FB, Simon D, Stieltjes B, Schad LR. An in vivo verification of the intravoxel incoherent motion effect in diffusion-weighted imaging of the abdomen. Magn Reson Med 2010, 64:1580-1585. 10.1002/mrm.22565, 20665824.
23. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast- enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010, 31:589-600. 10.1002/jmri.22081, 20187201.
24. Hintze C, Stemmer A, Bock M, Kuder TA, Risse F, Dinkel J, Prüm H, Puderbach M, Fink C, Biederer J, Kauczor HU. A hybrid breath hold and continued respiration-triggered technique for time-resolved 3D MRI perfusion studies in lung cancer. Rofo 2010, 182:45-52. 10.1055/s-0028-1109713, 19859857.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, . European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada New guidelines to evaluate the response to treatment in solid tumors. In J Natl Cancer Inst 2000, 92(3):205-216. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
26. Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008, 87:17-23. 10.1016/j.radonc.2008.02.005, 2722446, 18343515.
27. Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao Z. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small-cell lung cancer: The MD Anderson experience. Int J Radiat Oncol Biol Phys 2012, 83:332-339. 10.1016/j.ijrobp.2011.06.1963, 22079735.
28. Napadow VJ, Mai V, Bankier A, Gilbert RJ, Edelman R, Chen Q. Determination of regional pulmonary parenchymal strain during normal respiration using spin inversion tagged magnetization MRI. J Magn Reson Imaging 2001, 13:467-474. 10.1002/jmri.1068, 11241824.
29. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O'Donoghue J, Ling CC, Humm JZ, Zanzonico PB, Koutcher JA. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 2009, 11:247-259. 2647727, 19242606.
30. Jansen JF, Schöder H, Lee NY, Wang Y, Pfister DG, Fury MG, Stambuk HE, Humm JL, Koutcher JA, Shukla-Dave A. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18 F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys 2010, 77:1403-1410. 10.1016/j.ijrobp.2009.07.009, 2888682, 19906496.
31. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009, 50:1020-1027. 10.2967/jnumed.109.062638, 19525447.